Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal.
Animals
Antigens, Neoplasm
/ immunology
Biomarkers
Cells, Cultured
Clinical Studies as Topic
Coculture Techniques
Cytokines
/ metabolism
Epitopes, T-Lymphocyte
/ immunology
HLA Antigens
/ immunology
Humans
Immunotherapy, Adoptive
/ methods
Lymphocyte Activation
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Precision Medicine
/ methods
Protein Binding
T-Cell Antigen Receptor Specificity
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes
/ immunology
Treatment Outcome
adoptive cell therapy (ACT)
cancer immunotherapy
enrichment
neoantigens
tumor-infiltrating lymphocyte (TIL)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
03
2020
accepted:
15
05
2020
entrez:
23
7
2020
pubmed:
23
7
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Mutation-derived neoantigens are taking central stage as a determinant in eliciting effective antitumor immune responses following adoptive T-cell therapies. These mutations are patient-specific, and their targeting calls for highly personalized pipelines. The promising clinical outcomes of tumor-infiltrating lymphocyte (TIL) therapy have spurred interest in generating T-cell infusion products that have been selectively enriched in neoantigen (or autologous tumor) reactivity. The implementation of an isolation step, prior to T-cell
Identifiants
pubmed: 32695101
doi: 10.3389/fimmu.2020.01215
pmc: PMC7333784
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers
0
Cytokines
0
Epitopes, T-Lymphocyte
0
HLA Antigens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1215Informations de copyright
Copyright © 2020 Bianchi, Harari and Coukos.
Références
Nat Biotechnol. 2018 Nov 12;:
pubmed: 30418433
Sci Rep. 2019 Dec 12;9(1):18949
pubmed: 31831802
Nat Immunol. 2017 Aug;18(8):940-950
pubmed: 28628092
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
J Clin Invest. 2005 Jun;115(6):1616-26
pubmed: 15931392
Cell Rep. 2018 Apr 3;23(1):227-238.e3
pubmed: 29617662
Immunology. 2010 Jul;130(3):319-28
pubmed: 20408898
Nat Med. 2016 Apr;22(4):433-8
pubmed: 26901407
J Immunother. 2014 Nov-Dec;37(9):448-60
pubmed: 25304728
Trends Mol Med. 2017 Oct;23(10):869-871
pubmed: 28867556
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Sci Transl Med. 2013 Sep 18;5(203):203ra125
pubmed: 24048523
Nat Methods. 2009 Jul;6(7):520-6
pubmed: 19543285
Nat Biotechnol. 2019 Nov;37(11):1332-1343
pubmed: 31611695
Clin Cancer Res. 2017 Dec 1;23(23):7263-7275
pubmed: 28947567
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Cancer Res. 2018 Nov 15;24(22):5562-5573
pubmed: 29853601
J Immunother. 2012 Jun;35(5):400-8
pubmed: 22576345
Nat Med. 2019 May;25(5):767-775
pubmed: 31011208
Nat Commun. 2019 Jan 25;10(1):449
pubmed: 30683863
J Immunol. 2015 Dec 15;195(12):5827-36
pubmed: 26553072
J Immunol. 2013 Jun 15;190(12):6034-42
pubmed: 23690473
Curr Opin Biotechnol. 2020 Jan 8;65:52-59
pubmed: 31927304
J Clin Invest. 2015 Sep;125(9):3413-21
pubmed: 26258412
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Science. 2016 Jun 10;352(6291):1337-41
pubmed: 27198675
Nat Rev Cancer. 2003 Sep;3(9):666-75
pubmed: 12951585
Cancer Immunol Immunother. 2010 Sep;59(9):1425-33
pubmed: 20177676
Cell Rep. 2019 Sep 3;28(10):2728-2738.e7
pubmed: 31484081
Oncoimmunology. 2017 Sep 21;7(1):e1371895
pubmed: 29296522
Front Immunol. 2018 Jul 25;9:1716
pubmed: 30090105
Nat Med. 2001 Oct;7(10):1159-62
pubmed: 11590442
J Exp Med. 2018 Jan 2;215(1):141-157
pubmed: 29203539
Eur J Immunol. 1999 Dec;29(12):4053-9
pubmed: 10602016
J Clin Invest. 2015 Oct 1;125(10):3981-91
pubmed: 26389673
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
PLoS One. 2013;8(4):e60031
pubmed: 23560068
Nature. 2014 Nov 27;515(7528):572-6
pubmed: 25428506
Nat Biotechnol. 2019 Nov;37(11):1283-1286
pubmed: 31611696
J Immunol. 2004 Dec 15;173(12):7125-30
pubmed: 15585832
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
iScience. 2019 Nov 22;21:249-260
pubmed: 31677477
Nat Protoc. 2019 Jun;14(6):1687-1707
pubmed: 31092913
Cancer Immunol Immunother. 2017 May;66(5):657-666
pubmed: 28314956
J Immunol Methods. 2008 Nov 30;339(1):23-37
pubmed: 18760281
Cytometry A. 2008 Nov;73(11):1043-9
pubmed: 18561198
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
PLoS One. 2018 Nov 6;13(11):e0206654
pubmed: 30399156
Cancer Immunol Res. 2019 Nov;7(11):1824-1836
pubmed: 31484655
Ann Transl Med. 2016 Jul;4(14):262
pubmed: 27563649
Sci Rep. 2020 Mar 3;10(1):3914
pubmed: 32127601
Nat Protoc. 2015 Sep;10(9):1308-18
pubmed: 26247297
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Cancer Res. 2016 Oct 15;76(20):6006-6016
pubmed: 27742673
J Immunother. 2011 Apr;34(3):307-19
pubmed: 21389867
J Exp Med. 2016 Jun 27;213(7):1133-9
pubmed: 27242164
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Clin Cancer Res. 2014 May 1;20(9):2457-65
pubmed: 24634374
J Immunol Methods. 2011 Nov 30;374(1-2):26-34
pubmed: 21047511
Clin Cancer Res. 2012 Dec 15;18(24):6758-70
pubmed: 23032743
J Immunother. 2014 May;37(4):225-36
pubmed: 24714356
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724801
Cancer Immunol Res. 2015 Sep;3(9):992-8
pubmed: 26048577
Nat Commun. 2018 Jan 24;9(1):353
pubmed: 29367624
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Nat Med. 2006 Feb;12(2):246-51
pubmed: 16462803
Oncoimmunology. 2017 Mar 17;6(4):e1302631
pubmed: 28507809
Cancer Res. 2015 May 15;75(10):1983-91
pubmed: 25808864
Nat Genet. 2019 Jan;51(1):175-179
pubmed: 30510237
Front Immunol. 2019 Jun 24;10:1392
pubmed: 31293573
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
J Immunother. 2008 Oct;31(8):742-51
pubmed: 18779745
JCI Insight. 2018 Oct 4;3(19):
pubmed: 30282837
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43
pubmed: 17255287
N Engl J Med. 2016 Dec 8;375(23):2255-2262
pubmed: 27959684
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7437-42
pubmed: 20368442
Nat Commun. 2019 Feb 4;10(1):567
pubmed: 30718505
Cancer Immunol Immunother. 2014 Oct;63(10):1081-91
pubmed: 25099366
Front Immunol. 2017 Oct 10;8:1211
pubmed: 29067023
Science. 2014 May 9;344(6184):641-5
pubmed: 24812403
J Immunother. 2011 Apr;34(3):236-50
pubmed: 21389874
J Biol Chem. 2011 Dec 2;286(48):41723-35
pubmed: 21990358
J Immunol. 2015 Apr 1;194(7):3475-86
pubmed: 25725111
Cell. 2018 Sep 6;174(6):1586-1598.e12
pubmed: 30100188
Cancer Res. 2012 Apr 1;72(7):1642-50
pubmed: 22311675
Nat Med. 2013 Jun;19(6):747-52
pubmed: 23644516
Sci Immunol. 2017 Feb;2(8):
pubmed: 28367538
Mol Cell Proteomics. 2020 Feb;19(2):390-404
pubmed: 31848261
Front Immunol. 2018 Feb 07;9:199
pubmed: 29467769
Lancet Oncol. 2017 Aug;18(8):1009-1021
pubmed: 28694034
Nat Med. 2005 Oct;11(10):1113-7
pubmed: 16186817
Trends Biotechnol. 2014 Sep;32(9):456-65
pubmed: 24998519
Nat Methods. 2009 Jul;6(7):497-9
pubmed: 19543286
Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1921-5
pubmed: 7892200
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5536-E5545
pubmed: 29844168
Immunology. 2015 Sep;146(1):11-22
pubmed: 26076649
Nat Commun. 2018 Mar 15;9(1):1092
pubmed: 29545564
Cancer Immunol Res. 2018 Aug;6(8):888-899
pubmed: 29895573
J Immunother Cancer. 2018 Jul 13;6(1):70
pubmed: 30001747
Immunogenetics. 2015 Nov;67(11-12):641-50
pubmed: 26416257
J Clin Oncol. 2013 Nov 10;31(32):e439-42
pubmed: 24043743
Cancer Immunol Res. 2017 Jul;5(7):516-523
pubmed: 28619968
Oncoimmunology. 2015 May 21;4(5):e1002723
pubmed: 26155389
Cancer Discov. 2018 Nov;8(11):1366-1375
pubmed: 30209080
J Immunol Methods. 2007 Mar 30;320(1-2):119-31
pubmed: 17306825
J Clin Invest. 2019 Nov 1;129(11):4992-5004
pubmed: 31609250
Nat Commun. 2020 Feb 21;11(1):1000
pubmed: 32081859
Nature. 2015 Apr 30;520(7549):692-6
pubmed: 25901682
J Clin Invest. 2019 Feb 1;129(2):774-785
pubmed: 30640174
J Immunol. 2010 Jan 1;184(1):452-65
pubmed: 19949105
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
J Clin Oncol. 2006 Nov 1;24(31):5060-9
pubmed: 17075125
Nat Med. 2015 Jan;21(1):81-5
pubmed: 25531942
Clin Cancer Res. 2017 May 15;23(10):2491-2505
pubmed: 27827318
Nat Protoc. 2019 Jun;14(6):1926-1943
pubmed: 31101906
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Clin Cancer Res. 2014 Jan 15;20(2):434-44
pubmed: 24190978
J Immunol. 2015 Jul 1;195(1):356-66
pubmed: 26002978
Cancer Res. 2004 Sep 15;64(18):6783-90
pubmed: 15374997
J Immunol. 2007 May 1;178(9):5727-34
pubmed: 17442956
Eur J Immunol. 2016 Jun;46(6):1351-60
pubmed: 27005018
Sci Transl Med. 2019 Aug 21;11(506):
pubmed: 31434757
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394
Nat Biotechnol. 2016 Oct;34(10):1037-1045
pubmed: 27571370
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
J Immunol. 2008 May 1;180(9):6116-31
pubmed: 18424733
Cancer Immunol Res. 2016 Mar;4(3):204-14
pubmed: 26701267
Oncoimmunology. 2012 Jul 1;1(4):409-418
pubmed: 22754759
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
Nat Biotechnol. 2018 Nov 19;:
pubmed: 30451992
Nat Commun. 2020 Mar 10;11(1):1293
pubmed: 32157095